TD Capital Management LLC Sells 641 Shares of Merck & Co., Inc. (NYSE:MRK)

TD Capital Management LLC reduced its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 23.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,143 shares of the company’s stock after selling 641 shares during the quarter. TD Capital Management LLC’s holdings in Merck & Co., Inc. were worth $234,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in MRK. Bare Financial Services Inc bought a new position in Merck & Co., Inc. during the fourth quarter worth $28,000. Rakuten Securities Inc. acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $30,000. RIA Advisory Group LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $30,000. Tidemark LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $31,000. Finally, AlphaMark Advisors LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $34,000. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Down 1.1 %

NYSE:MRK traded down $1.43 on Thursday, reaching $124.47. 13,000,322 shares of the stock traded hands, compared to its average volume of 8,056,124. The firm has a market capitalization of $315.26 billion, a price-to-earnings ratio of 140.30, a price-to-earnings-growth ratio of 1.61 and a beta of 0.39. The company’s 50 day moving average is $128.43 and its 200-day moving average is $120.19. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.40 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 8.69 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.47%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MRK. Barclays lifted their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. UBS Group upped their price objective on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Berenberg Bank increased their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Truist Financial increased their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $131.33.

Read Our Latest Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.